全文获取类型
收费全文 | 3246篇 |
免费 | 190篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 76篇 |
妇产科学 | 55篇 |
基础医学 | 539篇 |
口腔科学 | 74篇 |
临床医学 | 337篇 |
内科学 | 715篇 |
皮肤病学 | 42篇 |
神经病学 | 298篇 |
特种医学 | 99篇 |
外科学 | 361篇 |
综合类 | 20篇 |
一般理论 | 1篇 |
预防医学 | 261篇 |
眼科学 | 44篇 |
药学 | 179篇 |
中国医学 | 3篇 |
肿瘤学 | 342篇 |
出版年
2024年 | 7篇 |
2023年 | 44篇 |
2022年 | 58篇 |
2021年 | 88篇 |
2020年 | 69篇 |
2019年 | 96篇 |
2018年 | 99篇 |
2017年 | 85篇 |
2016年 | 91篇 |
2015年 | 89篇 |
2014年 | 161篇 |
2013年 | 188篇 |
2012年 | 235篇 |
2011年 | 300篇 |
2010年 | 154篇 |
2009年 | 144篇 |
2008年 | 240篇 |
2007年 | 234篇 |
2006年 | 190篇 |
2005年 | 178篇 |
2004年 | 138篇 |
2003年 | 129篇 |
2002年 | 99篇 |
2001年 | 21篇 |
2000年 | 20篇 |
1999年 | 33篇 |
1998年 | 26篇 |
1997年 | 25篇 |
1996年 | 21篇 |
1995年 | 20篇 |
1994年 | 16篇 |
1993年 | 14篇 |
1992年 | 24篇 |
1991年 | 11篇 |
1990年 | 10篇 |
1989年 | 9篇 |
1988年 | 8篇 |
1987年 | 12篇 |
1986年 | 8篇 |
1985年 | 5篇 |
1984年 | 10篇 |
1983年 | 4篇 |
1982年 | 7篇 |
1981年 | 3篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1969年 | 2篇 |
1968年 | 3篇 |
1955年 | 2篇 |
排序方式: 共有3460条查询结果,搜索用时 15 毫秒
31.
Aggeliki Poulou Evgenia Grivakou Georgia Vrioni Vassiliki Koumaki Theodoros Pittaras Spyros Pournaras Athanassios Tsakris 《Journal of clinical microbiology》2014,52(5):1483-1489
The worldwide dissemination of Enterobacteriaceae producing AmpC β-lactamases and carbapenemases makes difficult the phenotypic detection of extended-spectrum β-lactamases (ESBLs), as they may be masked by these additional enzymes. A modification of the CLSI ESBL confirmatory test was developed and evaluated in a comparative study for its ability to successfully detect ESBLs among Enterobacteriaceae producing various carbapenemases (Klebsiella pneumoniae carbapenemase [KPC], VIM, NDM, and OXA-48) and plasmidic or derepressed AmpCs. The modified CLSI ESBL confirmatory test was performed with cefotaxime and ceftazidime disks with and without clavulanate, on which both boronic acid (BA) and EDTA were dispensed. A total of 162 genotypically confirmed ESBL-positive Enterobacteriaceae isolates (83 carbapenemase/ESBL producers, 25 AmpC/ESBL producers, and 54 ESBL-only producers) were examined. For comparison, 139 genotypically confirmed ESBL-negative Enterobacteriaceae isolates (94 of them possessed carbapenemases and 20 possessed AmpCs) were also tested. The standard CLSI ESBL confirmatory test was positive for 106 of the 162 ESBL producers (sensitivity, 65.4%) and showed false-positive results for 4 of the 139 non-ESBL producers (specificity, 97.1%). The modified CLSI ESBL confirmatory test detected 158 of 162 ESBL producers (sensitivity, 97.5%) and showed no false-positive results for non-ESBL producers (specificity, 100%). The findings of the study demonstrate that the modified CLSI ESBL confirmatory test using antibiotic disks containing both BA and EDTA accurately detects ESBLs in Enterobacteriaceae regardless of the coexistence of additional β-lactam resistance mechanisms. 相似文献
32.
M. Bardiès J.I. Gear 《Clinical oncology (Royal College of Radiologists (Great Britain))》2021,33(2):117-124
Molecular radiotherapy is a rapidly developing field with new vector and isotope combinations continually added to market. As with any radiotherapy treatment, it is vital that the absorbed dose and toxicity profile are adequately characterised. Methodologies for absorbed dose calculations for radiopharmaceuticals were generally developed to characterise stochastic effects and not suited to calculations on a patient-specific basis. There has been substantial scientific and technological development within the field of molecular radiotherapy dosimetry to answer this challenge. The development of imaging systems and advanced processing techniques enable the acquisition of accurate measurements of radioactivity within the body. Activity assessment combined with dosimetric models and radiation transport algorithms make individualised absorbed dose calculations not only feasible, but commonplace in a variety of commercially available software packages. The development of dosimetric parameters beyond the absorbed dose has also allowed the possibility to characterise the effect of irradiation by including biological parameters that account for radiation absorbed dose rates, gradients and spatial and temporal energy distribution heterogeneities. Molecular radiotherapy is in an exciting time of its development and the application of dosimetry in this field can only have a positive influence on its continued progression. 相似文献
33.
34.
Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects
下载免费PDF全文
![点击此处可从《European journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Florian Nolte Maximilian Mossner Johann‐Christoph Jann Daniel Nowak Tobias Boch Nadine Zoe Müller Wolf‐Karsten Hofmann Georgia Metzgeroth 《European journal of haematology》2017,98(3):302-310
Patients with monoclonal gammopathy of undetermined significance (MGUS) have a higher risk for the development of concomitant primary cancers such as multiple myeloma (MM) and myelodysplastic syndrome (MDS). We report the case of patient initially suffering from MGUS of the IgG lambda subtype for more than 10 yr, which evolved to MM and MDS with deletion (5q) with severe pancytopenia. Due to pancytopenia, he received dose‐reduced treatment with lenalidomide and dexamethasone. He achieved an ongoing transfusion independency after about 1 month of treatment. Bone marrow taken 14 months after start of treatment showed a complete cytogenetic response of the del(5q) clone and a plasma cell infiltration below 5%. In contrast to the development of MM in MGUS patients, the subsequent occurrence of MDS after diagnosis of MGUS is infrequent. Moreover, the biological association of MDS with MGUS is not sufficiently understood, but the non‐treatment‐related occurrence supports the pathogenetic role of pre‐existing alterations of stem cells. Here, we summarize data on concomitant MDS and MGUS/MM with particular emphasis on molecular aspects. 相似文献
35.
36.
37.
38.
39.
Yoav Michowitz Anat Milman Antoine Andorin Georgia Sarquella-Brugada M. Cecilia Gonzalez Corcia Jean-Baptiste Gourraud Giulio Conte Frederic Sacher Jimmy J.M. Juang Sung-Hwan Kim Eran Leshem Philippe Mabo Pieter G. Postema Aviram Hochstadt Yanushi D. Wijeyeratne Isabelle Denjoy Carla Giustetto Yuka Mizusawa Bernard Belhassen 《Journal of the American College of Cardiology》2019,73(14):1756-1765
Background
Information on young patients with Brugada syndrome (BrS) and arrhythmic events (AEs) is limited.Objectives
The purpose of this study was to describe their characteristics and management as well as risk factors for AE recurrence.Methods
A total of 57 patients (age ≤20 years), all with BrS and AEs, were divided into pediatric (age ≤12 years; n = 26) and adolescents (age 13 to 20 years; n = 31).Results
Patients’ median age at time of first AE was 14 years, with a majority of males (74%), Caucasians (70%), and probands (79%) who presented as aborted cardiac arrest (84%). A significant proportion of patients (28%) exhibited fever-related AE. Family history of sudden cardiac death (SCD), prior syncope, spontaneous type 1 Brugada electrocardiogram (ECG), inducible ventricular fibrillation at electrophysiological study, and SCN5A mutations were present in 26%, 49%, 65%, 28%, and 58% of patients, respectively. The pediatric group differed from the adolescents, with a greater proportion of females, Caucasians, fever-related AEs, and spontaneous type-1 ECG. During follow-up, 68% of pediatric and 64% of adolescents had recurrent AE, with median time of 9.9 and 27.0 months, respectively. Approximately one-third of recurrent AEs occurred on quinidine therapy, and among the pediatric group, 60% of recurrent AEs were fever-related. Risk factors for recurrent AE included sinus node dysfunction, atrial arrhythmias, intraventricular conduction delay, or large S-wave on ECG lead I in the pediatric group and the presence of SCN5A mutation among adolescents.Conclusions
Young BrS patients with AE represent a very arrhythmogenic group. Current management after first arrhythmia episode is associated with high recurrence rate. Alternative therapies, besides defibrillator implantation, should be considered. 相似文献40.
Maria Papaioannou Georgia Pitsiou Katerina Manika Paschalina Kontou Pavlos Zarogoulidis Lazaros Sichletidis 《COPD》2014,11(5):489-495
The COPD assessment test (CAT) is a short questionnaire designed to assess the impairment in health status of COPD patients. We aimed to determine the change of the CAT in COPD patients after 1 year of treatment and test the association between the score and clinical and lung function variables. Methods A cohort of 111 newly diagnosed COPD patients in primary care was evaluated at baseline and one year after the implementation of the recommended treatment according to the Global Initiative for the management of COPD (GOLD). Results Most of the patients (82%) were diagnosed with mild to moderate airflow limitation (mean FEV1 72 ± 21.5% predicted) and the CAT score increased in proportion with the GOLD stage of severity. The CAT significantly correlated with the number of exacerbations, visits to general practitioners and days of hospitalization both at the beginning and at 1 year follow-up. A strong negative correlation between the CAT score and FEV1 predicted was also observed. The CAT was responsive to the application of treatment with a significant improvement in the mean score (95% confidence interval) following 12 months of treatment by –2.4 (–2.9, –1.9) despite the small decline in lung function indices. The number of exacerbations in the preceding year and FEV1 were independent predictors of the CAT score in the general linear model. Conclusion The CAT questionnaire may serve as a simple, measurable tool complementary to spirometry in the assessment of severity and of response to treatment in unselected COPD patients in primary care. 相似文献